ACADIA Pharmaceuticals Inc.
ACAD
Classificação em ações
#4506
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Preço da ação
$19.76
Última sincronização: 2026-10-19
Valor de mercado
$3.40B
Variação (1 dia)
3.32%
Variação (1 ano)
-5.66%
País
US
Negociar ACADIA Pharmaceuticals Inc. (ACAD)
Categoria
Healthcare
Rácio P/S de ACADIA Pharmaceuticals Inc. (ACAD)
Rácio P/S em October 2026 TTM: 2.89
De acordo com os relatórios financeiros mais recentes e o preço das ações da ACADIA Pharmaceuticals Inc., o rácio P/S atual (TTM) é 2.89. No final de 2023, o rácio P/S era 7.06.
Histórico do rácio P/S da ACADIA Pharmaceuticals Inc. de 2000 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 2.89 | -8.68% |
| 2024 | 3.17 | -55.03% |
| 2023 | 7.06 | 41.88% |
| 2022 | 4.98 | -35.68% |
| 2021 | 7.74 | -59.36% |
| 2020 | 19.04 | 2.52% |
| 2019 | 18.57 | 103.07% |
| 2018 | 9.15 | -69.06% |
| 2017 | 29.56 | -84.67% |
| 2016 | 192.80 | -99.67% |
| 2015 | 58.81K | 128.57% |
| 2014 | 25.73K | 1,275.39% |
| 2013 | 1.87K | 3,498.15% |
| 2012 | 51.99 | 90.69% |
| 2011 | 27.27 | 2,380.70% |
| 2010 | 1.10 | -85.78% |
| 2009 | 7.73 | -63.20% |
| 2008 | 21.01 | -59.28% |
| 2007 | 51.59 | 70.96% |
| 2006 | 30.18 | 52.49% |
| 2005 | 19.79 | 30.01% |
| 2004 | 15.22 | 1,049.01% |
| 2003 | 1.32 | -14.53% |
| 2002 | 1.55 | -28.86% |
| 2001 | 2.18 | 31.07% |
| 2000 | 1.66 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | 246.20% |
US
|
|
| 40.55 | 1,300.77% |
US
|
|
| 3.96 | 36.83% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 250.49% |
NL
|
